STOCK TITAN

BIOTRICITY INC 8-K Filings

BTCY OTC

Every 8-K that BIOTRICITY INC (BTCY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 8-K covers material events a company has to report between its quarterly reports, so if you follow BTCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTCY filings page.

Rhea-AI Summary

Biotricity Inc. entered exchange agreements on May 1, 2026 with holders of 14,144,325 common shares, options for 3,992,427 shares, and warrants for 1,436,216 shares. These securities were exchanged for 1,957,297 shares of newly created Series C Preferred Stock on a ten‑for‑one basis.

The company designated 2,100,000 Series C Preferred shares, each carrying 40 votes. After any equity financing raising at least $15 million, outstanding Series C will automatically convert into 59.6% of Biotricity’s common stock. If no such financing occurs by March 31, 2028, each Series C share may convert into 10 common shares.

Rhea-AI Summary

Biotricity Inc. reported solid third-quarter fiscal 2026 results, with revenue rising 10.2% to $4 million from $3.6 million a year earlier. The company highlighted its third consecutive quarter of positive EBITDA and net operating income, reflecting growing adoption of its remote cardiac monitoring solutions.

Gross margin improved to 81.5% from 76.4%, helped by a larger recurring technology-fee base and AI-driven efficiencies. Net loss narrowed to $1.1 million, or $0.042 per share, compared with $1.3 million, or $0.054 per share. Management also pointed to strong customer retention above 90% and ongoing international expansion.

Rhea-AI Summary

Biotricity Inc. reported that it has released its financial results for the period ended September 30, 2025. The company announced these results through a press release dated November 14, 2025, which is included as Exhibit 99.1. The notice clarifies that this earnings information is being furnished under a current report and is not deemed filed for liability purposes under the securities laws unless specifically incorporated by reference elsewhere.